Muntinlupa Mayor Jaime Fresnedi said the city government is preparing to start the registration of adolescents aged 12 to 17 years old for vaccination against coronavirus disease (COVID-19).
The registration will be handled by the Muntinlupa City COVID-19 Vaccination Program team, which currently supervises the inoculation of residents and essential workers.
The move follows other local government units (LGUs), which have opened the registration for the age group.
As of Sept. 8, 192,360 individuals have been fully vaccinated in Muntinlupa or 49.9 percent of the target population of 385,725.
A total of 319,963 individuals received their first dose or 83 percent of the target population. The tally included 11,404 individuals who were vaccinated in Muntinlupa private companies.
According to MunCoVac, 507,964 vaccine doses were administered as of Sept. 8 since the city started its vaccination program in March.
Last Sept. 2, the country’s Food and Drug Administration (FDA) approved the use of the Moderna vaccine for 12 years and above.
This after Zuellig Pharma Corp. requested FDA to amend the original Emergency Use Authorization (EUA) dated Aug. 12, which allowed Modern to be used for 18 years old and above.
“This applies to the request to amend the Emergency Use Authorization dated 12 August 2021 for the COVID-19 mRNA Vaccine (Nucleoside Modified) (COVID-19 Vaccine Moderna) Dispersion for Injection (I.M.) (COVID-19 Vaccine Moderna) to expand the therapeutic indication to 12 years of age and older. After due consideration, the Food and Drug Administration (FDA) hereby revises the EUA granted to COVID-19 Vaccine Moderna as requested,” the FDA told Zuellig Pharma in a letter.
The FDA approved the use of Modern for at least 12 years old “based on the totality of evidence available to date, including data from adequate and well- known controlled trials, it is reasonable to believe that the COVID-19 Vaccine Moderna may be effective to prevent, diagnose, or treat COVID-1.”
“The known and potential benefits of the COVID-19 Vaccine Moderna, when used to diagnose, prevent or treat COVID-19, outweigh the known and potential risks of said Vaccine as of date; and there is currently no adequate, approved and available alternative to the product for diagnosing, preventing or treating COVID-19,” the FDA added.
According to the FDA, the Moderna vaccine is a two-dose vaccine with the second dose administered after 28 days.